This is a prospective, multicenter, randomized, controlled, two-arm, non-inferiority study which will be conducted in China to support registration of a cephalomedullary nailing system (TFNA) that currently is available globally. The study will compare the safety and the effectiveness of two intramedullary nails (the investigational group is TFNA and the control group is PFNA-II).Patients enrolled at each site will be randomized in a ratio of 1:1, i.e. one patient assigned to surgery implanted with TFNA for each patient assigned to PFNA-II. Separate block randomization schedules within each site will be used to ensure equal distribution of treatment and control patients. Up to 15 centers will be approved to participate in this study.

Patient will be clinically followed after surgery at 1, 6, 12 and 24 weeks. The data up to and including 24 week follow up visit will be used in determining the primary safety and effectiveness of the TFNA.

The primary objective of this study is to evaluate whether fracture union rate, evaluated 24 weeks after proximal femur fracture, for the investigational TFNA intramedullary nail is non-inferior to that for currently available control product PFNA-II in patients with proximal femur fractures.

Inclusion Criteria:

1. Age ≥18 years

2. Patients with unilateral proximal femur fractures that will be treated with intramedullary nail internal fixation

3. According to AO fracture classification, subjects with following fracture type:

   1. Pertrochanteric (31-A1 and 31-A2)
   2. Intertrochanteric (31-A3)
   3. Trochanteric area (31-A1/A2/A3) with diaphyseal extension

4. Subject must be comfortable with speaking and understanding questions and responses in an available translated language for patient reported outcomes (PROs)

Exclusion Criteria:

1. Subject does not provide voluntary consent to participate in the study
2. The subject is a woman who is pregnant or lactating
3. Fractures where the operative treatment will occur more than three weeks after the primary injury
4. Patients with femoral head fractures and femoral neck fractures (AO classification 31-B and 31-C)
5. Pathological fracture (e.g., primary or metastatic tumor)
6. Serious soft tissue injury, judged by the investigator, will impact the union of the fracture, combined vascular injury, and combined osteofascial compartment syndrome
7. Multiple systemic injuries judged by researchers not suitable for enrollment, or orthopaedic fractures in other bones at three or more sites
8. Revision surgeries (for example, due to malunion, nonunion or infection)
9. Concurrent medical conditions judged by researchers not suitable for enrollment, such as: diabetes, metabolic bone disease, post-polio syndrome, poor bone quality, prior history of poor fracture healing, etc
10. Patients with anaesthetic and surgical contraindications
11. Patients known to be allergic to implant components
12. Patients who are currently using chemotherapeutics or accepting radiotherapy, use systematically corticosteroid hormone or growth factor, or long-term use sedative hypnotics (continuous use over 3 months) or non-steroidal anti-inflammatory drugs (continuous use over 3 months)
13. Intemperance judged by researchers not suitable for enrollment (e.g., excessive daily drinking or smoking, drug abuse);
14. Patients participated into other clinical trial in the previous 3 months;
15. Patients with bad compliance judged by researchers and cannot complete the test according to test scheme, such as schizophrenia and dementia.

3 subjects were not implanted with any device, so total 185 subjects were included in FAS.

Adverse events and serious adverse events were recorded starting at the time of subject randomization, until subject completion of study (24 weeks follow-up visit after surgery). All AEs were followed until the AE resolved, stabilized, or the study was completed.

Judged the relationship between them and the products, and summarized the occurrence types of AEs for the safety evaluation of the product.

Only patient is masked during the study. He/she will be notified during inform consent that either treatment will be used but they will not be informed exactly which group.